Towards Healthcare
Hemophilia Market Size Expects to Project USD 27.27 Billion by 2034

Hemophilia Market Trends, Personalized Medicine and Precision Therapies

According to market projections, the hemophilia sector is expected to grow from USD 14.34 billion in 2024 to USD 27.27 billion by 2034, reflecting a CAGR of 6.64%. Hemophilia affects over 1.1M globally, often undiagnosed. Advances like gene therapy and long-acting treatments are reshaping care. In 2024, North America led the market share by 50%, while Europe grows fast. Hemophilia A, prophylaxis, and factor therapy dominate, with cures and gene therapy rising fast.

Content

  • Last Updated: 01 July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

Although there is not a definitive cure for hemophilia at this time, new treatments like gene therapy provide patients who have the condition hope for long-term care and maybe a more normal life.

Hympavzi is a novel kind of medication that functions by decreasing the quantity and, consequently, the activity of the naturally occurring anticoagulant protein known as tissue factor pathway inhibitor, as opposed to substituting a clotting factor.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions